BCRX
Closed
Biocryst Pharmaceuticals Inc
9.
0 (0.00%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 8.96
Day's Range: 8.885 - 9.11
Send
sign up or login to leave a comment!
When Written:
8.34
BioCryst Pharmaceuticals Inc. is a biotechnology company that develops and commercializes innovative medicines to treat rare diseases. The company was founded in 1986 and is headquartered in Durham, North Carolina, USA. BioCryst's focus is on the development of small molecule drugs that target enzymes involved in disease processes. The company's lead drug candidate is Orladeyo (berotralstat), an oral medication for the prevention of hereditary angioedema (HAE) attacks. BioCryst also has several other drug candidates in development, including BCX9930 for the treatment of complement-mediated diseases and BCX9250 for the treatment of fibrodysplasia ossificans progressiva (FOP). The company has partnerships with several pharmaceutical companies, including Roche, Seqirus, and Mundipharma, to develop and commercialize its products. BioCryst is publicly traded on the NASDAQ stock exchange under the ticker symbol BCRX.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








